Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Pancreatic islet transplantation (PIT) offers a physiological treatment for type 1 diabetes, but the failure of islet engraftment hinders its application. The female hormone 17β-oestradiol (E2) favours islet survival and stimulates angiogenesis, raising the possibility that E2 may enhance islet engraftment following PIT. METHODS: To explore this hypothesis, we used an insulin-deficient model with xenotransplantation of a marginal dose of human islets in nude mice rendered diabetic with streptozotocin. This was followed by 4 weeks of treatment with vehicle, E2, the non-feminising oestrogen 17α-oestradiol (17α-E2), the oestrogen receptor (ER) α agonist propyl-pyrazole-triol (PPT), the ERβ agonist diarylpropionitrile (DPN) or the G protein-coupled oestrogen receptor (GPER) agonist G1. RESULTS: Treatment with E2, 17α-E2, PPT, DPN or G1 acutely improved blood glucose and eventually promoted islet engraftment, thus reversing diabetes. The effects of E2 were retained in the presence of immunosuppression and persisted after discontinuation of E2 treatment. E2 produced an acute decrease in graft hypoxic damage and suppressed beta cell apoptosis. E2 also acutely suppressed hyperglucagonaemia without altering insulin secretion, leading to normalisation of blood glucose. CONCLUSIONS/INTERPRETATION: During PIT, E2 synergistic actions contribute to enhancing human islet-graft survival, revascularisation and functional mass. This study identifies E2 as a short-term treatment to improve PIT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“Currently, most immunosuppressed type 1 diabetic recipients of human islets allotransplant [3, 4] can successfully attain insulin independence and protection from hypoglycaemia at 1 year.”
BackgroundMethodFive stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126 · cited 1×
“Evidence suggests that as little as 20% of the islets within a pancreas are required to maintain euglycaemia [5].”
BackgroundDupont, S., Krust, A., Gansmuller, A., Dierich, A., Chambon, P., & Mark, M. (2000) · Development · doi:10.1242/dev.127.19.4277 · Cited by 1,064
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“Indeed, total insulin deficiency by beta cell destruction in glucagon-receptor-null mice, which are unresponsive to glucagon, does not cause diabetic abnormalities [41].”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“This observation is consistent with the concept that insulin suppresses glucagon secretion from alpha cells via paracrine mechanisms [43] and that insulin signalling in alpha cells is required for this process [44].”
ResultGlucagon: Role in the Hyperglycemia of Diabetes Mellitus
Dobbs, R., Sakurai, H., Sasaki, H., Faloona, G., Valverde, I., Baetens, D., Orci, L., & Unger, R. (1975) · Science · doi:10.1126/science.1089999 · Cited by 229
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Cited by
The role of estrogens in control of energy balance and glucose homeostasis
Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329
Self-citationMauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1146 · Cited by 341
Self-citationProssnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
Kaliannan, K., Robertson, R. C., Murphy, K., Stanton, C., Kang, C., Wang, B., Hao, L., Bhan, A. K., & Kang, J. X. (2018) · Microbiome · doi:10.1186/s40168-018-0587-0 · Cited by 253
Sharma, G., Hu, C., Brigman, J. L., Zhu, G., Hathaway, H. J., & Prossnitz, E. R. (2013) · Endocrinology · doi:10.1210/en.2013-1357 · Cited by 210
“Finally, the GPER-selective agonist G-1 (32) attenuates -cell death in the MIN6 pancreatic -cell line as well as in mouse and human islets (31) and promotes islet survival following transplantation in a murine model of type 1 diabetes (33).”
Background
Metadata
- Authors
- Liu, S., Kilic, G., Meyers, M. S., Navarro, G., Wang, Y., Oberholzer, J., & Mauvais-Jarvis, F.
- Venue
- Diabetologia
- Published
- 2012-11-07
- Volume
- 56
- Issue
- 2
- Pages
- 370-381
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2148509762
- Cited by
- 73
- References
- 8
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. https://app.cochat.ai/papers/10.1007/s00125-012-2764-1
- The paper
- Liu, S., Kilic, G., Meyers, M. S., Navarro, G., Wang, Y., Oberholzer, J., & Mauvais-Jarvis, F. (2013). Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia. https://doi.org/10.1007/s00125-012-2764-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.